BIOCONTROL TECHNOLOGY INC
8-K, 1999-04-08
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: AFL CIO HOUSING INVESTMENT TRUST, N-30B-2, 1999-04-08
Next: BIOCONTROL TECHNOLOGY INC, 8-K, 1999-04-08





               SECURITIES AND EXCHANGE COMMISSION

                     Washington, D.C.  20549

                            FORM 8-K

                         CURRENT REPORT

             Pursuant to Section 13 or 15(d) of the
                 Securities Exchange Act of 1934

                       ___________________


 Date of Report (Date of earliest event reported) March 29, 1999

                   BIOCONTROL TECHNOLOGY, INC.
     (Exact name of registrant as specified in its charter)


  Pennsylvania                      0-10822               25-1229323
(State of other jurisdiction  (Commission File Number)   (IRS Employer
  of incorporation)                                      Identification No.)


      300 Indian Springs Road, Indiana, Pennsylvania 15701
    (Address of principal executive offices)    (Zip Code)


Registrant's telephone number, including area code (412) 349-1811



_________________________________________________________________
                 (Former name or former address,
                  if changes since last report.)







Item 1.   Change in Control of Registrant.
          Not applicable.

Item 2.   Acquisition or Disposition of Assets.
          Not applicable.

Item 3.   Bankruptcy or Receivership.
          Not applicable.

Item 4.   Changes in Registrant's Certifying Accountant
          Not applicable.

Item 5.   Other Events.

          Biocontrol Technology, Inc. announced today, that a
          Diasensor 1000 Noninvasive Blood Glucose Monitor was
          delivered to the Food and Drug Administration (FDA)
          following  the conclusion of a technical seminar
          presented to FDA staff members at the Company's
          Indiana, PA facilities on March 23 and 24, 1999.   The
          FDA purchased the Diasensor 1000, which is already
          approved for sale in the 15-country European Union, in
          order to evaluate its performance characteristics and
          conduct laboratory and clinical research on noninvasive
          monitoring.

Item 6.   Resignation of Registrant's Directors.
          Not Applicable

Item 7.   Financial Statement, Pro Forma Financial Information
          and Exhibits.

          (a)  Financial Statements and Businesses Acquired
               Not Applicable.

          (b)  Pro Forma Financial Information - Not Applicable.

          (c)  Exhibits - Press Release.

                           SIGNATURES

      Pursuant to the requirement of the Securities Exchange  Act
of  1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.

                                   BIOCONTROL TECHNOLOGY, INC.

                                   by  /s/   Fred E. Cooper
                                             Fred E. Cooper, CEO

DATED:  March 29, 1999


                                        BICO
                                       BIOCONTROL TECHNOLOGY, INC
                            2275 Swallow Hill Road, Building 2500
                                            Pittsburgh, PA  15220
Press Release

Investors                                     Media
Diane McQuaide                                Susan Taylor
1.412.429.0673  phone                         1.412.429.0673 phone
1.412.279.9690  fax                           1.412.279.5041 fax



              BIOCONTROL DELIVERS DIASENSOR 1000 TO THE FDA

     Pittsburgh,  PA  -  March 29, 1999 - Biocontrol  Technology,
Inc.   (OTCBB:BICO)  announced  today,  that  a  Diasensor   1000
Noninvasive Blood Glucose Monitor was delivered to the  Food  and
Drug Administration (FDA) following the conclusion of a technical
seminar  presented to FDA staff members at the Company's Indiana,
PA facilities on March 23 and 24, 1999.

     The  FDA  purchased  the Diasensor 1000,  which  is  already
approved  for sale in the 15-country European Union, in order  to
evaluate  its performance characteristics and conduct  laboratory
and clinical research on noninvasive monitoring.  The purpose  of
the  seminar  was  to  educate the attending  FDA  staff  members
regarding  the  application, operation, and  maintenance  of  the
device.    Biocontrol  will  continue  to  assist  the  FDA,   as
requested, in their study of this new noninvasive technology.

     David  L.  Purdy, president of Biocontrol, stated  "The  FDA
personnel who attended the seminar were very knowledgeable  about
existing  invasive glucose testing technology, and the Biocontrol
presentation was designed to extend FDA personnel's understanding
of  the  Company's noninvasive technology used in  the  Diasensor
1000.   Both the FDA and Biocontrol personnel profited  from  the
interchange of concepts embodied in the Diasensor."

     Biocontrol   Technology  has  its   corporate   offices   in
Pittsburgh, PA and is involved in the development and manufacture
of  biomedical devices and environmental products. Biocontrol has
the   exclusive  rights  to  the  research  and  development  and
manufacturing  of  the Diasensor 1000. Subsidiary  Diasensor.com,
Inc.,  also located in Pittsburgh, PA, owns the patent, marketing
and distribution rights to the sensor.

WEBSITE:  www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER:  1.800.357.6204








© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission